Findings add to the understanding of centanafadine’s potential in the treatment of ADHD in adults Centanafadine is currently under Priority Review by the FDA, with a target action date of July 24, ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced new post hoc, exploratory analyses from two identical Phase 3 clinical trials ...
PRINCETON, N.J. & TOKYO, May 28, 2026--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced new post hoc, ...
It seems we can never escape the appeal of French-girl beauty, whether it’s the signature featherlight wash of color on the lips or the most famous bangs in the world. Treehouse Studio founder Travis ...
SAN FRANCISCO--(BUSINESS WIRE)--Highlight AI, the intelligent operating system for teams and AI agents, today announced a $40 million Series A funding round led by Khosla Ventures, with participation ...
DALLAS, March 23, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with ...
Electroacupuncture Promotes Neural Repair by Inhibiting Calcium-Driven ER Stress After Spinal Cord Injury. Schematic illustration of the proposed mechanism by which electroacupuncture at the Shenshu ...
An international research team has uncovered new insights into healthy brain aging. The researchers found that aging leads to the accumulation of defective energy molecules in the brains of aged mice, ...
Hosted on MSN
Navigating intimacy and disability
A thoughtful exploration of how disability impacts intimacy, relationships, and bodily functions, highlighting challenges, adaptations, and personal stories. Iran demands uranium enrichment rights in ...
About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and irritability as well as increased health risks like diabetes and heart risks if ...
Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results